SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in ...
NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel
Source: eagletribune.com